Thyroid cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BRAF 15
• RET 8
• PI3K 0
• TP53 0
• TERT 0
• MAPK 1
• GLP-1 1
• AKT 0
• PTEN 0
• STAT3 0
• mTOR 0
• NTRK 2
• PD-1 5
• RAS 1
• ERK 0
• MEK 1
• PSMA 1
• ALK 1
• EGFR 3
• VEGF 2
• PD-L1 0
• JAK 0
• KRAS 1
• CTNNB1 0
• NRAS 2
• NRF2 0
• PPAR 0
• TROP2 3
• AMPK 0
• DLL3 2
• HIF-1 0
• PIK3CA 0
• ABL1 0
• DPP-4 0
• IL-6 1
• METTL3 0
• TNF 0
• YAP 0
• AXL 1
• EZH2 0
• FGFR 0
• JNK 0
• MET 1
• MYC 0
• PKM2 0
• ROS1 1
• SGLT2 0
• STING 0
• ATM 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CDKN2A 0
• CGRP 0
• CTLA-4 0
• CXCR4 0
• FAK 0
• GPX4 0
• HMGB1 0
• IDH 0

24 of 1,051 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Improving Efficacy of TSHR-CART by Targeting Suppressive Myeloid Cells

  Mayo Clinic Rochester· Rochester, United States· US$50,114 awarded in fiscal year 2026· until Jul 2029

• NIH NCI · P01

  ImpACT: Improving Treatment Strategies for Anaplastic Thyroid Cancer Through Integration of Novel Therapies and Assessment of Tumor Response

  University of Tx Md Anderson Can Ctr· Houston, United States· US$2,709,149 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  MRI-based Active Bone Marrow Imaging and Segmentation for Patient-Specific Radiopharmaceutical Therapy Dosimetry

  University of Wisconsin-Madison· Madison, United States· US$530,194 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Structural and mechanistic studies of the RAS/RAF MAPkinase pathway

  Dana-Farber Cancer Inst· Boston, United States· US$657,443 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · F31

  Investigating the mechanism and clinical utility of keratin switching in thyroid cancer

  Vanderbilt University· Nashville, United States· US$35,582 awarded in fiscal year 2026· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication (A-PONTE)

  Universita Degli Studi di Torino· Torino, Italy· EU contribution €2,497,392· until Dec 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Chemotherapy-induced Alopecia - Relief Managed by Engineered Silk (CARMESilk)

  Friedrich-Schiller-Universität Jena· Jena, Germany· EU contribution €401,232· until Sept 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence (InnoThyroGen)

  Sveuciliste U Splitu Medicinski Fakultet· Split, Croatia· EU contribution €4,937,275· until Dec 2028· 2 countries

8 of 77 running projects, newest first. Listed amounts together: US$45.6m + €7.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Updated 5 Nov 2026

  “\< 75 % participation”Registry text, quoted unchanged. Source

• Suspended

  Personalized Treatment in Thyroid Disorders

  NCT03517579· Johns Hopkins University· Updated 22 Oct 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Suspended

  Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

  NCT03975231· City of Hope Medical Center· Updated 15 Oct 2026

  “Accrual goal met”Registry text, quoted unchanged. Source

• Terminated

  HEC169096 in Participants With Advanced Solid Tumors

  NCT05451602· Sunshine Lake Pharma Co., Ltd.· Updated 14 Oct 2026

  “Sponsor strategic decision; the study will not continue.”Registry text, quoted unchanged. Source

• Terminated

  Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

  NCT05575440· Mayo Clinic· Updated 24 Sept 2026

  “Slow accrual; lack of eligible study participants”Registry text, quoted unchanged. Source

• Withdrawn

  RAman For Thyroid cancER

  NCT04040673· Gloucestershire Hospitals NHS Foundation Trust· Updated 17 Sept 2026

  “Covid19 halted study”Registry text, quoted unchanged. Source

• Suspended

  CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

  NCT07181720· Chongqing Precision Biotech Co., Ltd· Updated 11 Sept 2026

  “Sponsor stopped the study.”Registry text, quoted unchanged. Source

• Suspended

  Methimazole in Patients With Progressive Glioblastoma

  NCT05607407· Case Comprehensive Cancer Center· Updated 17 Aug 2026

  “On hold per study team”Registry text, quoted unchanged. Source

• Suspended

  Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

  NCT05453799· Northwestern University· Updated 14 Aug 2026

  “Per sponsor letter, due to a business decision based on reprioritization of their internal XmAb20717 programs, Xencor has determined that ECR003 activities must halt and no additional subjects may be enrolled”Registry text, quoted unchanged. Source

• Terminated

  Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery

  NCT05591092· Mayo Clinic· Updated 11 Aug 2026

  “Slow accrual”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· National Cancer Institute (NCI)· Source

• Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

  NCT03914300· National Cancer Institute (NCI)· Source

• Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

  NCT04104529· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Predictive Value of microRNA in Thyroid Cytologies of Undetermined Type

  NCT04285476· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Natural History Study of Children and Adults With Medullary Thyroid Cancer

  NCT01660984· National Cancer Institute (NCI)· Source

• The Application of Electrical Stimulation in Postoperative Pain Management of Thyroid Surgery

  NCT06931743· Xiaonan Huang· Source

• Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma

  NCT07911761· Mansoura University· Source

• Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

  NCT01005654· National Cancer Institute (NCI)· Source

• Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

  NCT07886905· Washington University School of Medicine· Source

• A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

  NCT01896479· Exelixis· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 6
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 3
• Gene Expression Profiling 65
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 1
• Exome Sequencing 7
• Proteomics 14
• Metabolomics 9
• Mass Spectrometry 7
• Flow Cytometry 6
• Immunohistochemistry 72
• Liquid Biopsy 9
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 57
• Positron-Emission Tomography 44
• Magnetic Resonance Imaging 18
• Machine Learning 72
• Deep Learning 44
• Cohort Studies 118
• Genome-Wide Association Study 16

• FPSA, a potential risk factor for thyroid nodules by gender: A cohort study in China.

  Int J Biol Markers, Oct 2026

• Radiofrequency versus microwave ablation for non-functioning benign thyroid nodules: a single-institution comparative cohort study.

  Endocrine, Oct 2026

• Second primary malignancy risk following radioactive iodine therapy for thyroid cancer: a population-based matched cohort study in Taiwan.

  Eur J Endocrinol, Oct 2026

• Expanding the Molecular Data of DICER1-Related Tumor Predisposition: Novel Germline Variants in an Argentine Pediatric Cohort.

  Hum Mutat, Sept 2026

• Validation of a thyroid malignancy risk calculator in a Portuguese cohort.

  Endocrine, Sept 2026

• Beyond Tumor Diameter: Exploratory Cohort-Derived Calcitonin Secretory Categories and Invasive Pathology in Medullary Thyroid Carcinoma.

  Curr Oncol, Sept 2026

• Sex and Mortality Among Patients with Papillary Thyroid Cancer.

  JAMA Netw Open, Sept 2026

• Cancer Risk Among Young Adults With Clinically Diagnosed Fatty Liver Disease: A Nationwide Cohort Study in South Korea.

  Cancer Med, Sept 2026

• Radiation Risk of Screening-Detected Diffuse Goiter in a Belarusian Cohort Exposed as Children or Adolescents to Iodine-131 after Chernobyl.

  Cancer Epidemiol Biomarkers Prev, Sept 2026

• APOC1-Associated VLDL-Pathway Dysregulation in Papillary Thyroid Carcinoma: A Reproducible Cross-Cohort Transcriptomic Signature Associated With the Diagnostic-to-Treatment Interval.

  Chem Biol Drug Des, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.